LABD vs. XTAP
LABD (Direxion Daily S&P Biotech Bear 3x Shares) and XTAP (Innovator U.S. Equity Accelerated Plus ETF) are both Leveraged Equities funds. LABD is passively managed, while XTAP is actively managed. Over the past 5 years, LABD returned -47.09%/yr vs 10.92%/yr for XTAP. At a correlation of -0.51, they often move in opposite directions. LABD charges 1.06%/yr vs 0.79%/yr for XTAP.
Performance
LABD vs. XTAP - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LABD achieves a -58.72% return, which is significantly lower than XTAP's 11.99% return.
LABD
- 1D
- 8.60%
- 1M
- -31.85%
- 6M
- -55.64%
- YTD
- -58.72%
- 1Y
- -85.70%
- 3Y*
- -58.22%
- 5Y*
- -47.09%
- 10Y*
- -58.05%
XTAP
- 1D
- -0.25%
- 1M
- 0.74%
- 6M
- 11.66%
- YTD
- 11.99%
- 1Y
- 18.69%
- 3Y*
- 16.74%
- 5Y*
- 10.92%
- 10Y*
- —
LABD vs. XTAP - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
LABD Direxion Daily S&P Biotech Bear 3x Shares | -58.72% | -70.07% | -21.43% | -41.77% | -32.68% | 18.40% |
XTAP Innovator U.S. Equity Accelerated Plus ETF | 11.99% | 17.58% | 14.26% | 23.46% | -14.68% | 12.26% |
Correlation
The correlation between LABD and XTAP is -0.38, meaning they tend to move in opposite directions. This is especially valuable for risk management - when one declines, the other has historically tended to hold steady or rise.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.38 |
Correlation (3Y) Calculated over the trailing 3-year period | -0.47 |
Correlation (5Y) Calculated over the trailing 5-year period | -0.52 |
Correlation (All Time) Calculated using the full available price history since Apr 1, 2021 | -0.51 |
The correlation between LABD and XTAP shifts across timeframes, from -0.52 (5 years) to -0.38 (1 year), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LABD vs. XTAP — Risk / Return Rank
LABD
XTAP
LABD vs. XTAP - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Direxion Daily S&P Biotech Bear 3x Shares (LABD) and Innovator U.S. Equity Accelerated Plus ETF (XTAP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LABD | XTAP | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -5.02 | ||
| Sortino ratioReturn per unit of downside risk | -9.12 | ||
| Omega ratioGain probability vs. loss probability | 0.72 | 2.00 | -1.28 |
| Calmar ratioReturn relative to maximum drawdown | -0.96 | 10.94 | -11.89 |
| Martin ratioReturn relative to average drawdown | -1.33 | 57.97 | -59.30 |
Loading charts...
Drawdowns
LABD vs. XTAP - Drawdown Comparison
The maximum LABD drawdown since its inception was -100.00%, which is greater than XTAP's maximum drawdown of -22.13%. Use the drawdown chart below to compare losses from any high point for LABD and XTAP.
Loading charts...
Drawdown Indicators
| LABD | XTAP | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -22.13% | -77.87% |
Max Drawdown (1Y)Largest decline over 1 year | -89.59% | -1.72% | -87.87% |
Max Drawdown (3Y)Largest decline over 3 years | -97.43% | -11.83% | -85.60% |
Max Drawdown (5Y)Largest decline over 5 years | -99.04% | -22.13% | -76.91% |
Max Drawdown (10Y)Largest decline over 10 years | -99.99% | — | — |
Current DrawdownCurrent decline from peak | -99.99% | -0.25% | -99.74% |
Average DrawdownAverage peak-to-trough decline | -91.04% | -3.39% | -87.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 64.54% | 0.32% | +64.22% |
Volatility
LABD vs. XTAP - Volatility Comparison
Direxion Daily S&P Biotech Bear 3x Shares (LABD) has a higher volatility of 25.77% compared to Innovator U.S. Equity Accelerated Plus ETF (XTAP) at 1.48%. This indicates that LABD's price experiences larger fluctuations and is considered to be riskier than XTAP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LABD | XTAP | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 25.77% | 1.48% | +24.29% |
Volatility (6M)Calculated over the trailing 6-month period | 65.70% | 3.83% | +61.87% |
Volatility (1Y)Calculated over the trailing 1-year period | 79.35% | 4.77% | +74.58% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 96.77% | 14.55% | +82.22% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 95.75% | 14.28% | +81.47% |
LABD vs. XTAP - Expense Ratio Comparison
LABD has a 1.06% expense ratio, which is higher than XTAP's 0.79% expense ratio.
Dividends
LABD vs. XTAP - Dividend Comparison
LABD's dividend yield for the trailing twelve months is around 7.61%, while XTAP has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
LABD Direxion Daily S&P Biotech Bear 3x Shares | 7.61% | 6.67% | 4.68% | 6.13% | 0.53% | 0.00% | 3.94% | 1.75% | 0.81% |
XTAP Innovator U.S. Equity Accelerated Plus ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
LABD and XTAP have a correlation of -0.38, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LABD has higher volatility (25.77%) compared to XTAP (1.48%). In terms of maximum drawdown, LABD dropped -100.00% vs XTAP's -22.13%.
On 5-year performance, XTAP leads with 10.92% vs -47.09% for LABD. On fees, XTAP is cheaper at 0.79% per year. On volatility, XTAP has been the lower-risk option at 1.48%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, XTAP has performed better with a 10.92% return vs -47.09%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
XTAP is cheaper with a 0.79% expense ratio, compared with 1.06% for LABD.
LABD has the higher dividend yield at 7.61%, compared with 0.00% for XTAP.
They also come from different issuers: Direxion and Innovator. Their fees differ too: 1.06% for LABD and 0.79% for XTAP.
XTAP currently has the higher Sharpe Ratio (3.93 vs -1.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LABD and XTAP
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer